# Ladera Medical Presents Full FASTEN Results Showing Rapid Hemostasis and a Strong Safety Profile with its Large Bore Closure System

- Link: https://www.thailand-business-news.com/pr-news/ladera-medical-presents-full-fasten-results-showing-rapid-hemostasis-and-a-strong-safety-profile-with-its-large-bore-closure-system
- Published: 2026-11-22T17:15:00+07:00
- Author: PR Newswire

|   |

_Late-breaking data from 55 TAVR/TAVI patients presented at London Valves 2026._

LONDON, Nov. 22, 2026 /PRNewswire/ — Ladera Medical today announced full results
from the FASTEN clinical trial of the Ladera Large Bore Closure System in patients
undergoing transfemoral transcatheter aortic valve replacement/implantation (TAVR/
TAVI). Jan van der Heyden, MD, Interventional Cardiologist at St. Jan Hospital in
Bruges, Belgium, presented the data in a Late-Breaking Clinical Trials session at
London Valves 2026. In 55 patients, the Ladera LBC System achieved a mean time to
hemostasis of 0.5 ± 2.0 minutes, with 98.1% freedom from major access-site complications
at 30 days.

FASTEN is a prospective, multicenter, single-arm clinical study that enrolled 55
patients at six sites in Australia, Belgium, and the Netherlands. The primary safety
endpoint was freedom from major complications of the target-limb access site through
30 days, as adjudicated by an independent clinical events committee (CEC). The primary
efficacy endpoint was mean time to hemostasis in the common femoral artery. Secondary
endpoints included minor access-site complications, technical success, treatment
success and time to ambulation.

Key results from the full study cohort include:

 ◦ Freedom from major access-site complications at 30 days: 98.1% (52/53)
 ◦ Freedom from minor access-site complications at 30 days: 98.1% (52/53)
 ◦ Mean time to hemostasis: 0.5 ± 2.0 minutes (median 0 minutes)
 ◦ Technical success: 94.5% (52/55)
 ◦ Treatment success, defined as technical success with freedom from major complications:
   94.3% (50/53)
 ◦ Mean time to ambulation: 14.3 ± 14.5 hours

"These results show that a suture-based system built for large bore closure can 
achieve fast, reliable hemostasis with a low rate of major access-site complications
at 30 days," said Dr. van der Heyden. "Operators find this device to be intuitive,
and it can be used pre-close or post-close. Just as important, guidewire access 
is maintained throughout closure, so there is always a way to bail out if something
doesn’t go as planned."

Large bore transcatheter procedures are among the fastest growing segments of cardiovascular
care, driven largely by the continued expansion of transfemoral TAVR/TAVI. Although
these procedures have become less invasive and more routine, closure of the femoral
access site remains a significant source of complications, including bleeding and
vascular injury and can extend both procedure time and length of stay.

"In Australia, as in much of the world, TAVI has become routine, but the move to
large bore access has exposed real limits in how we close these sites, and complications
at the access site remain a persistent risk," said Associate Professor Robert Gooley,
Head of Interventional Cardiac Services at Monash Health in Melbourne, Australia
and a leading enroller in FASTEN who presented the study’s preliminary results at
EuroPCR 2026. "Today we either combine several small-bore suture devices on a very
large arteriotomy or use a device that leaves material inside the artery. There 
has been a real need for a single device that delivers suture closure at this size,
and I believe we finally have one."

The Ladera System is an innovative, suture-mediated vascular closure device designed
to achieve hemostasis following large-bore percutaneous cardiovascular procedures.
The system utilizes a unique closure mechanism that deploys two parallel sutures
simultaneously to facilitate secure and effective closure of femoral arterial access
sites. Suture-based closure is widely regarded as the gold standard for these cases
because it leaves no large implant in the artery and preserves the vessel for future
access. However, existing suture devices were designed for small bore punctures 
and typically require two or more devices per access site. The Ladera Closure System
is designed for closure of 10F to 24F arteriotomies with a single device and the
sutures can be deployed either before the procedure (pre-close) or after it (post-
close) while maintaining guidewire access.

The Ladera LBC System is limited by Federal law to investigational use and not available
for sale in any country.

**About Ladera Medical Ladera Medical is a private medtech company based in Menlo
Park, California, focused on safe, reliable closure of large bore femoral access
sites. The company is developing the Ladera Large Bore Closure System, a suture-
mediated vascular closure device designed to close large bore arteriotomies with
a single device using either a pre-close or post-close approach. For more information,
visit laderamedical.com.

**Media Contact **

Jen Fitzgerald 
[jen@sprigconsulting.com](https://www.thailand-business-news.com/pr-news/jen@sprigconsulting.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ladera Medical Presents Full FASTEN Results Showing Rapid Hemostasis and a Strong Safety Profile with its Large Bore Closure System ](https://en.prnasia.com/story/archive/5103894_AE03894_0?rand=184833)
